SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by a softer fourth-quarter outlook and a reduced advertising forecast, renewing concerns about slowing growth and prompting analyst downgrades. Traders are divided between viewing the selloff as an overreaction and expecting further weakness amid content and competition concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Strong Q3 results, including a return to profitability and rapid AI-compute growth, have prompted a sharp rally and a wave of analyst price-target increases. Bulls see the results as evidence of expanding demand, while skeptics point to heavy capital spending and scheduled share unlocks as risks of overvaluation and added selling pressure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets selloff ahead of earnings has traders focused on AI spending and whether Cloud and AI growth can justify the investment; claims that capital spending may double remain speculation. Dip buyers point to the companys AI and Cloud position, while bears worry about weak returns on spending, pressure on Search, and further downside.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment includes To-Home businesses, which include Ele.me, local services and delivery platforms, and Taoxianda, and To-Destination segment businesses, which include Amap, the provider of mobile digital maps, navigation and real-time traffic information, and restaurant and local services guide platforms. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solutions. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibabas pullback amid weakness across Chinese equities is driving discussion, with traders pointing to pressure on Hong Kong tech and uncertainty over Beijing support rather than a clear company-specific catalyst. Bears see a persistent China-related value trap, while bulls argue the decline is overdone and look for signs of support and a rebound.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros sharply raised preliminary revenue and gross-margin outlook, attributed to strong AI-server demand, is driving the rally. Many traders see the update as a bullish turnaround and discuss short-covering, while others question whether gains will hold and whether margins, cash flow, and execution can sustain the growth.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention amid sharp swings in memory and semiconductor stocks after a steep pullback, with traders debating whether concerns about AI spending and Chinese competitor CXMT are overstated and whether the rebound can hold ahead of earnings. Bulls cite AI-driven memory demand and anticipate strong results, while bears point to cyclicality, selling pressure, and the risk of further declines.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in the AI neocloud selloff as investors focus on financing risks at CoreWeave and Piper Sandler lowered its view of the sector. Bulls counter that compute demand remains strong and cite Nebiuss CRO saying customer prepayments and its funding mix make it less exposed to debt concerns, while traders also point to SpaceXs demand commentary as support for the AI infrastructure thesis.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet shares are drawing attention for a sharp selloff and weak technical action ahead of earnings, with traders debating whether broad market pressure or concerns about AI and data-center spending are weighing on the stock. The community is split between seeing the decline as a buying opportunity and warning that further weakness could follow if earnings fail to reassure investors about cloud growth and spending returns.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Despite a quarterly earnings beat, shares are under pressure as traders focus on the antitrust settlement charge and narrower da Vinci procedure-growth outlook, alongside planned instrument pricing reductions. The community is split between viewing the growth and selloff as overdone and seeing the outlook and pricing changes as reasons for caution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is drawing attention around clinical data presented at the MS conference, particularly early azer-cel results in progressive MS showing encouraging safety and disability signals, alongside long-term BRIUMVI and dosing updates. Traders see potential pipeline and commercial upside, but some are frustrated by the muted share-price reaction and emphasize that the azer-cel findings come from a small, uncontrolled study.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The FDA also cleared the company’s Investigational New Drug application.</li><li>The full 100-week results from the first part of the trial are expected in the second half of 2026.</li><li>AC Immune has total cash resources of $92.9 million, which it expects to fund operations into the fourth quarter of 2027.</li></ul>Shares of AC Immune (ACIU) surged more than 16% on Tuesday, after the U.S. Food and Drug Administration granted Fast Track designation to its experimental immunotherapy for early-stage Parkinson’s disease.<a href="https://stocktwits.com/symbol/ACIU">ACIU shares</a> are on track to clock their biggest intraday gains since October 2025.<h2 class="st-heading-2">FDA Clears Investigational New Drug Application</h2>Fast Track designation is intended for treatments targeting serious diseases with unmet medical needs. It allows AC Immune to communicate with the FDA more frequently during the trials. AC Immune’s ACI-7104 could also become eligible for accelerated approval or priority review if it meets the relevant requirements.However, the designation does not mean that the treatment has been approved or that its effectiveness has been established.The FDA also cleared the company’s Investigational New Drug (IND) application, allowing the ongoing Phase 2 VacSYn study to expand to clinical sites in the U.S.<h2 class="st-heading-2">Full Results Expected In Second Half Of 2026</h2>ACI-7104 is designed to generate antibodies that target toxic, aggregated forms of a protein called alpha-synuclein. The buildup of this protein is linked to inflammation and the loss of brain cells associated with Parkinson’s disease.Interim results from the trial showed that the therapy was generally safe and well tolerated through 76 weeks, with no clinically significant safety concerns. All treated patients produced the targeted immune response, giving the study a 100% responder rate.The full 100-week results from the first part of the trial are expected in the second half of 2026. According to AC Immune’s quarterly statements last week, the firm has total cash resources of CHF75.4 million ($92.9 million), which it expects to fund operations into the fourth quarter of 2027.<h2 class="st-heading-2">ACIU Bulls Eye Breakout</h2>Retail sentiment surrounding ACIU on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes.One user said the fast-track designation could lead to the stock breaking out “soon.”<stembedurl>https://stocktwits.com/BLD33/message/661530497</stembedurl>ACIU shares have declined more than 25% so far in 2026.(Exchange Rate: CHF1 = $1.23)Also read: <a href="https://stocktwits.com/news-articles/markets/equity/citi-says-hims-and-hers-full-year-outlook-indicates-hefty-q4-earnings-lift-warns-of-execution-risks/cZoNbc5RJQC">Citi Says Hims &amp; Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The U.S. Food and Drug Administration granted Fast Track designation to AC Immune’s experimental immunotherapy ACI-7104 for early-stage Parkinson’s disease.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.51
Prev Close	$2.49
Open	$2.50
Dividend Yield	0.00%
50-Day Moving Average	$2.65
Beta	1.03
Avg. Volume	166,054.53
PE Ratio	-4.48

52-Week High	$4.00
52-Week Low	$2.10
Market Capitalization	$253.42M
EPS (Annual)	-$0.8419
Price to Book	5.20
Revenue Per Employee	$35,264.75

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACIU Fundamentals